drugset / Trial / NCT04845191
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
RandomizedSequentialTriple-blindTreatment
Summary
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19. This clinical trial is designed to assess the safety, efficacy, reactogenicity, and immunogenicity of hAd5-S-Fusion+N-ETSD formulated for subcutaneous and oral (capsule) administration.
Timeline
- Start
- 2021-12
- Primary completion
- 2021-12
- Completion
- 2021-12-14
Outcome
Outcome not reported
Stopped: “The sponsor has changed the development plans which is not for safety reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 1e+10 iu | Subcutaneous |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 5e+10 iu | Subcutaneous |